EPS for Simulations Plus, Inc. (SLP) Expected At $0.10

Simulations Plus, Inc. (NASDAQ:SLP) Logo
Investors sentiment decreased to 1.39 in Q4 2018. Its down 0.06, from 1.45 in 2018Q3. It is negative, as 4 investors sold Simulations Plus, Inc. shares while 24 reduced holdings. 13 funds opened positions while 26 raised stakes. 6.54 million shares or 6.05% more from 6.16 million shares in 2018Q3 were reported.
Marshall Wace Llp, a United Kingdom-based fund reported 24,204 shares. 3,158 were accumulated by Jpmorgan Chase. Northern Trust Corp, a Illinois-based fund reported 163,341 shares. Retail Bank Of America Corporation De, a North Carolina-based fund reported 8,754 shares. Granite Investment Ltd Limited Liability Company has 36,354 shares for 0.05% of their portfolio. Prudential Inc reported 0% stake. Deutsche State Bank Ag reported 15,797 shares. Fmr Lc invested in 0% or 123 shares. Ranger Invest Mngmt Limited Partnership has 0.62% invested in Simulations Plus, Inc. (NASDAQ:SLP) for 379,944 shares. Oppenheimer Asset Management holds 4,247 shares. Rhumbline Advisers accumulated 15,309 shares or 0% of the stock. Stanley holds 63,024 shares. Tower Rech Cap Llc (Trc) owns 519 shares. Renaissance Technology Ltd has 0.01% invested in Simulations Plus, Inc. (NASDAQ:SLP) for 616,300 shares. The Minnesota-based First Light Asset Mngmt Limited Liability Company has invested 0.8% in Simulations Plus, Inc. (NASDAQ:SLP).

Since September 27, 2018, it had 0 insider buys, and 3 insider sales for $1.08 million activity.

Analysts expect Simulations Plus, Inc. (NASDAQ:SLP) to report $0.10 EPS on April, 8.They anticipate $0.01 EPS change or 9.09 % from last quarter’s $0.11 EPS. SLP’s profit would be $1.75 million giving it 51.28 P/E if the $0.10 EPS is correct. After having $0.09 EPS previously, Simulations Plus, Inc.’s analysts see 11.11 % EPS growth. The stock decreased 0.15% or $0.03 during the last trading session, reaching $20.51. About 49,105 shares traded. Simulations Plus, Inc. (NASDAQ:SLP) has risen 32.05% since March 17, 2018 and is uptrending. It has outperformed by 27.68% the S&P500.

Simulations Plus, Inc. develops and sells drug discovery and development software for mechanistic modeling and simulation. The company has market cap of $358.10 million. The firm offers GastroPlus, which simulates the absorption, pharmacokinetics , and pharmacodynamics of drugs administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments, which measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments. It has a 41.86 P/E ratio. It also provides PKPlus, a standalone program that provides the functionality needed by pharmaceutical industry scientists to perform the analyses and generate the outputs needed to satisfy regulatory agency requirements for NCA and compartmental PK modelling; ADMET Predictor, a chemistry computer program, which takes molecular structures as inputs and predicts their properties; and MedChem Designer, a molecule drawing program or sketcher that integrates with MedChem Studio and ADMET Predictor.

More notable recent Simulations Plus, Inc. (NASDAQ:SLP) news were published by: Seekingalpha.com which released: “Shorting Simulations Plus Is Silly – Seeking Alpha” on February 23, 2016, also Seekingalpha.com with their article: “The Good Business Portfolio Will Not Buy Amazon – Seeking Alpha” published on February 20, 2019, Seekingalpha.com published: “If You Can Take The Risk, Simulations Plus Has Fantastic Potential – Seeking Alpha” on July 08, 2018. More interesting news about Simulations Plus, Inc. (NASDAQ:SLP) were released by: Nasdaq.com and their article: “WD-40 Company (WDFC) Ex-Dividend Date Scheduled for January 17, 2019 – Nasdaq” published on January 16, 2019 as well as Nasdaq.com‘s news article titled: “INVENTIVA: 2018 Full-Year Results : Important Progress in R&D Portfolio and Solid Cash Position – Nasdaq” with publication date: February 27, 2019.

Simulations Plus, Inc. (NASDAQ:SLP) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.